

LUNG-MAP

A lung cancer precision medicine trial

VOLUME 26 | FALL 2024

NEWSLETTER

WWW.LUNG-MAP.ORG

Lung-MAP 3.0: A Pragmatic Approach to Genomic Screening

LUNGMAP protocol revision #9 is live, with a major expansion of genomic screening options that marks the third generation of Lung-MAP: Lung-MAP 3.0.

This means you can now submit tissue test results from almost any CLIA-certified next-generation sequencing (NGS) platform that is sufficiently broad (≥ 150 markers) to have your patient assigned to a Lung-MAP treatment sub-study at disease progression.

You can find the list of allowable testing platforms – now at more than 40 tests, from both commercial and academic labs – linked from swog.org/lung-map-resources. Several blood-based tests that are approved for Lung-MAP screening are also identified.

The vast majority of NGS tests now used with these patients are already listed. And more will be added regularly.

We've also developed a process for rapid review and approval of new assays, so you can email us at LungMAPNGS@swog.org and get an answer *in real time* (usually within a day) about whether your patient's results from *assay X* can be used to assign them to a Lung-MAP sub-study.

On-study genomic screening using the Foundation Medicine platform remains available, and at no cost to your patients, either as pre-screening or at the time of disease progression.

The Lung-MAP 3.0 approach makes the trial more pragmatic – you can have your patients screened for Lung-MAP using the NGS platforms you and your patients already use (note that some sub-studies may have more specific testing requirements).

When your patient with NSCLC has disease progression, or when their NGS results show a rare subtype, think Lung-MAP.

S1900J is Open: Subcutaneous Amivantamab in NSCLC with MET Amplification

S1900J activated earlier this fall! This biomarker sub-study is enrolling **patients with MET amplification** in stage IV or recurrent non-small cell lung cancer (NSCLC). Patients must not have other actionable oncogenic alterations and must not have been treated previously with a MET tyrosine kinase inhibitor.

All participants on S1900J are treated with subcutaneous amivantamab, a bispecific antibody targeting both EGFR and MET. This is one of the first non-industry sponsored studies of amivantamab given subcutaneously. Subcutaneous administration should take less time than intravenous, a benefit for both patients and sites.

S1900J is looking to enroll 88 participants, who will be stratified into squamous cell and non-squamous cell cohorts. The trial is also banking circulating tumor DNA (ctDNA) starting at baseline, to evaluate next-generation sequencing using ctDNA.

Drs. Shirish Gadgeel and Christian Rolfo are leading the S1900J sub-study, with biostatistical leadership by Dr. Mary Redman and Katherine Minichiello, MS.

Because MET amplification is a particularly complicated biomarker, only a subset of the Lung-MAP-

LUNG-MAP
LUNGMAP NGS Testing Reference Page
Approved Commercial and Academic Laboratories
As of 11/22/2024

Approved tissue-based NGS testing laboratories include:

Commercial Laboratories:

- BostonGene (Tumor Portrait Test)
- Caris Life Sciences (M Tumor Seek Hybrid)
- Exact Sciences, Inc. (OncoExTra)
- Foundation Medicine (FoundationOne CDx)
- Genomic Testing Cooperative (Solid Tumor Profile)
- Myriad Genetics (Precise Tumor)
- NeoGenomics Laboratories (Neo Comprehensive – Solid Tumor)
- PathGroup (SmartGenomes Complete)
- Quest Diagnostics Inc. (Solid Tumor Expanded Panel)
- Paradigm Diagnostic Informatics (pPortrait, Comprehensive NGS)
- Strata Oncology (Strata Select)
- Tempus (xT Solid Tumor)
- The Jackson Laboratory (BOMASEQ)

Academic Laboratories:

- Augusta University
- Brigham and Women's Hospital
- Cedars-Sinai Medical Center
- Children's Hospital of Philadelphia
- City of Hope National Medical Center
- Columbia University
- Dana-Farber Cancer Institute
- Fox Chase Cancer Center
- Frederick National Laboratory for Cancer Research
- Johns Hopkins Genomics
- Knight Diagnostic Laboratories at Oregon Health & Science University
- Massachusetts General Hospital
- Memorial Sloan-Kettering Cancer Center
- Moffitt Cancer Center
- National Cancer Institute – Laboratory of Pathology
- Providence Genomics
- Stanford Health Care
- Texas Children's Hospital
- The University of Texas MD Anderson Cancer Center
- University of California San Francisco
- University of Colorado
- University of Illinois Chicago
- University of Michigan
- University of Washington
- Weill Cornell Medicine
- Yale University

Page 1 of 3

CONTINUED ON NEXT PAGE


LEARN MORE AT WWW.LUNG-MAP.ORG



S1900J FROM PAGE 1


accepted NGS assays will be accepted for assigning patients to S1900J. Consult the Lung-MAP Sub-Studies Reference Table linked from swog.org/lung-map-resources for the current list of allowable assays for this sub-study.

Finally, when presenting S1900J to patients, hand them a copy of the sub-study's patient-friendly trial summary, online and in PDF format at swog.org/S1900J.



Lung-MAP is an umbrella trial for patients with advanced NSCLC with rare alterations and molecular subtypes. It works best when sites offer Lung-MAP's full suite of biomarker sub-studies to these patients!

- **S1900E:** for NSCLC with a KRAS^{G12C} gene mutation:
 - Cohort 1 (co-mutation with TP53) – FULL and closed to accrual
 - Cohort 2 (co-mutation with STK11) – FULL and closed to accrual
 - Cohort 3 (all other co-mutations, or no co-mutation) – OPEN (expected to close soon)
- **S1900G:** for NSCLC with an EGFR mutation and with MET amplification *at progression*
- **S1900J:** for NSCLC with MET amplification
- **S1900K:** for NSCLC with a MET exon 14-skipping gene change
- **S1800E:** *our next non-match sub-study – standard of care plus or minus an anti-PD1 antibody – will open very soon!*



Find the complete Lung-MAP Sub-Studies Reference Table, the growing list of approved NGS-based tests, and much more at swog.org/lung-map-resources.

S1900G EDUCATIONAL WEBINAR – FEB 5, 2025, 12-1 PM CT

“Optimizing Care for Patients with EGFR-Mutant Lung Cancer: A Focus on S1900G and EA5182”
Register at <https://swog.webex.com/weblink/register/rd0cd0ef47ec0cc52afc085d1dd5b652b>

How Do I Read an NGS Results Report?

To request Lung-MAP sub-study assignment for a patient based on previous NGS test results, you must complete the LUNGMAP Genomic Alterations Form in Rave. This form asks you to consult the patient's results report and record its findings on two dozen specific genomic alterations – present or absent.

To help you quickly find this information in these reports, the Lung-MAP team is developing guides for the most common NGS platforms. Each guide lists where results for each alteration can be found in the given report, followed by an annotated sample of that report.



The guides are available at swog.org/lung-map-resources, in the **LUNGMAP NGS Test Guides and Sample Reports** section. New guides will be added regularly.

KEY BIOMARKER FINDINGS				POTENTIAL CLINICAL TRIALS
KEY BIOMARKERS	FDA-APPROVED DRUGS -for patient's cancer-	FDA-APPROVED DRUGS -for another cancer-	DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT	
TUMOR GENOMIC ALTERATIONS				
ARID1A (S249*)				Yes
CD74/ROS1 (Fusion)	crizotinib, entrectinib	cabozantinib, ceritinib, lorlatinib		Yes
NF1 (Q369*)		binimetinib, erasorinib, temozolimus, trametinib		Yes
TP53 (R96T)				Yes
TUMOR MUTATION BURDEN (TMB)				
INTERMEDIATE (8 mut/Mb)				No
MICROSATELLITE STATUS (MSI)				
STABLE				No
IHC RESULTS				
PD-L1 (22C3): Low	atezolizumab, durvalumab, nivolumab, pembrolizumab	dostarlimab-gly		
HIGH INTEREST BIOMARKERS				

Lung-MAP Patient-Friendly Summaries: ¡En Español!

Spanish-language versions of patient-friendly summaries are now available for all Lung-MAP sub-studies. These are prominently linked from the English-language versions:


- swog.org/S1900E
- swog.org/S1900G
- swog.org/S1900J
- swog.org/S1900K
- swog.org/S1800E (soon!)



TOP-ACCRUING SITES TO LUNGMAP*

UPMC Hillman Cancer Center	Pittsburgh, PA	154
Edwards Comprehensive Cancer Center	Huntington, WV	80
UNM Comprehensive Cancer Center	Albuquerque, NM	74
Wilmot Cancer Institute Univ of Rochester	Rochester, NY	60
Palo Alto Medical Foundation – Sunnyvale	Sunnyvale, CA	54
Missouri Baptist Medical Center	St. Louis, MO	51
Harold Alfond Center for Cancer Care	Augusta, ME	51
Cleveland Clinic Mercy Medical Center	Canton, OH	49
VA Connecticut Healthcare System – West Haven	West Haven, CT	40
Dartmouth Hitchcock Med Ctr/Dartmouth Cancer Ctr	Lebanon, NH	39
Eastern Maine Medical Center Cancer Care	Brewer, ME	39
Baystate Medical Center	Springfield, MA	38
UC Davis Comprehensive Cancer Center	Sacramento, CA	37
AnMed Health Cancer Center	Anderson, SC	37

* As of December 12, 2024



**AS OF DECEMBER 12, 2024,
THE NEW LUNGMAP
PROTOCOL HAS LOGGED:**

3,541
screening registrations

1,755
sub-study assignments

493
sub-study registrations

CONTACT US

Request Review of New NGS Test
LungmapNGS@swog.org

General Medical Questions
LUNGMAP@swog.org

Protocol & Regulatory Questions
jbeeler@swog.org

Eligibility & Data Submission Questions
LUNGMAPQuestion@crab.org

Central Monitoring Questions
centralmonitorquestion@crab.org

Quality Assurance Auditing Questions
qamail@swog.org

Funding Questions
funding@swog.org

S1900E Study Chairs
S1900EMedicalQuery@swog.org

S1900G Study Chairs
S1900GMedicalQuery@swog.org

S1900J Study Chairs
S1900JMedicalQuery@swog.org

S1900K Study Chairs
S1900KMedicalQuery@swog.org

The latest list of acceptable NGS tests for Lung-MAP screening is at swog.org/lung-map-resources.
Click on "LUNGMAP NGS Testing Reference Page."